ArticleIJU case reports2026
A Case of Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus Achieving Pathologic Complete Response Following Combination Therapy With Lenvatinib and Pembrolizumab.
Article in IJU case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The efficacy of neoadjuvant lenvatinib plus pembrolizumab for clear cell renal cell carcinoma with inferior vena cava tumor thrombus remains unclear. Case Presentation: An 80-year-old man was diagnosed with clear cell renal cell carcinoma and tumor thrombus extending into the inferior vena cava. Following neoadjuvant lenvatinib plus pembrolizumab, the primary renal tumor shrank markedly, whereas the inferior vena cava tumor thrombus demonstrated only a slight reduction in size. Robot-assisted radical nephrectomy and lymphadenectomy were performed; however, conversion to open surgery was required because of an inferior vena cava laceration. Pathological examination revealed no residual viable cancer cells. The patient has remained free of recurrence for 1.5 years postoperatively. Conclusion: In this case, a pathological complete response was achieved following combination therapy of lenvatinib with pembrolizumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.